Vaccines have become a central instrument of our long-term response to the pandemic. Vaccination campaigns have now started around the world and will confer significant direct protection against infection, severe illness, and death to those inoculated. It may also protect against transmission, though robust evidence is yet to be confirmed.
CGD Policy Blogs
Research findings are most impactful when considered a global public good, accessible by anyone, and, for publicly funded research, there is no reason why this should not be the case. The current research publishing system—dominated by a number of large for-profit publishers—is expensive and ineffective at its main goal: disseminating the findings of research to all who need them. While the myriad problems of research publishing in high-income countries are often overcome by simply paying up, this option may not be available to many in low- and middle-income countries.
In 2020, epidemiological modelling went from relative obscurity to being central in helping governments, and the public, understand COVID-19 as it spread around the world. In 2021, with the emergence of effective COVID-19 vaccines, Health Technology Assessment (HTA) will be critical to making the best possible decisions in bringing the pandemic under control, particularly in low-and middle-income countries (LMICs). In this blog we look at the potential of HTA to inform how much vaccine countries should buy, who should pay, and how vaccines can be most effectively delivered.